Aging with HIV: The Burden of Comorbidities, Polypharmacy, and Drug Interactions in Korean People Living with HIV Aged ≥50 Years.

IF 2.8 Q2 INFECTIOUS DISEASES
Jin Kim, Hyun-Ju Nam, Ji-Yeon Kim, Mi-Kyung Heo, Sung Un Shin, Uh Jin Kim, Seong Eun Kim, Seung-Ji Kang, Jihwan Bang, Jin-Soo Lee, Mi-Ok Jang, Kyung-Hwa Park
{"title":"Aging with HIV: The Burden of Comorbidities, Polypharmacy, and Drug Interactions in Korean People Living with HIV Aged ≥50 Years.","authors":"Jin Kim, Hyun-Ju Nam, Ji-Yeon Kim, Mi-Kyung Heo, Sung Un Shin, Uh Jin Kim, Seong Eun Kim, Seung-Ji Kang, Jihwan Bang, Jin-Soo Lee, Mi-Ok Jang, Kyung-Hwa Park","doi":"10.3947/ic.2024.0132","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The life expectancy of people living with human immunodeficiency virus (PLWH) has significantly improved with advancements in antiretroviral therapy (ART). However, aging PLWH face a growing burden of non-communicable diseases (NCDs), polypharmacy, and drug-drug interactions (DDIs), which pose challenges in their management. This study investigates the prevalence of NCDs, polypharmacy, and DDIs among PLWH aged ≥50 years in Korea and their impact on quality of life (QOL).</p><p><strong>Materials and methods: </strong>A cross-sectional study was conducted among 243 PLWH aged ≥50 years receiving ART for at least three months at three university hospitals in Korea between January and July 2022. Data were collected through electronic medical records and personal interviews, assessing demographics, comorbidities, polypharmacy, ART adherence, and QOL using the Korean version of WHOQOL-HIV BREF scale. Potential DDIs were analyzed using the University of Liverpool HIV Drug Interaction Database, and potentially inappropriate medications (PIMs) were identified using the 2023 American Geriatrics Society Beers Criteria. We classified participants into three age groups: 50-<65 years, 65-<75 years, and ≥75 years.</p><p><strong>Results: </strong>The prevalence of comorbidities was 71.6%, with older participants (≥75 years) showing a significantly higher burden, including bone diseases, osteoarthritis, and dementia (<i>P</i><0.001). Polypharmacy was observed in 28.4% of participants and increased with age, with 53.3% of those aged ≥75 years taking ≥10 pills daily. Polypharmacy was associated with poorer QOL (71.6 <i>vs.</i> 76.6, <i>P</i>=0.010). Amber-flag DDIs were found in 81 participants (33.3%), most commonly involving metformin and divalent cations. No red-flag DDIs were identified. PIMs were observed in 6.6% of participants aged ≥65 years.</p><p><strong>Conclusion: </strong>Aging PLWH in Korea face significant challenges from comorbidities, polypharmacy, and DDIs, which negatively impact QOL. Integrated, age-specific, and multidisciplinary care strategies are urgently needed to improve outcomes and ensure the well-being of older PLWH.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":"56 4","pages":"534-543"},"PeriodicalIF":2.8000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11704864/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infection and Chemotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3947/ic.2024.0132","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The life expectancy of people living with human immunodeficiency virus (PLWH) has significantly improved with advancements in antiretroviral therapy (ART). However, aging PLWH face a growing burden of non-communicable diseases (NCDs), polypharmacy, and drug-drug interactions (DDIs), which pose challenges in their management. This study investigates the prevalence of NCDs, polypharmacy, and DDIs among PLWH aged ≥50 years in Korea and their impact on quality of life (QOL).

Materials and methods: A cross-sectional study was conducted among 243 PLWH aged ≥50 years receiving ART for at least three months at three university hospitals in Korea between January and July 2022. Data were collected through electronic medical records and personal interviews, assessing demographics, comorbidities, polypharmacy, ART adherence, and QOL using the Korean version of WHOQOL-HIV BREF scale. Potential DDIs were analyzed using the University of Liverpool HIV Drug Interaction Database, and potentially inappropriate medications (PIMs) were identified using the 2023 American Geriatrics Society Beers Criteria. We classified participants into three age groups: 50-<65 years, 65-<75 years, and ≥75 years.

Results: The prevalence of comorbidities was 71.6%, with older participants (≥75 years) showing a significantly higher burden, including bone diseases, osteoarthritis, and dementia (P<0.001). Polypharmacy was observed in 28.4% of participants and increased with age, with 53.3% of those aged ≥75 years taking ≥10 pills daily. Polypharmacy was associated with poorer QOL (71.6 vs. 76.6, P=0.010). Amber-flag DDIs were found in 81 participants (33.3%), most commonly involving metformin and divalent cations. No red-flag DDIs were identified. PIMs were observed in 6.6% of participants aged ≥65 years.

Conclusion: Aging PLWH in Korea face significant challenges from comorbidities, polypharmacy, and DDIs, which negatively impact QOL. Integrated, age-specific, and multidisciplinary care strategies are urgently needed to improve outcomes and ensure the well-being of older PLWH.

与HIV一起衰老:韩国≥50岁HIV感染者的合并症负担、多种用药和药物相互作用
背景:随着抗逆转录病毒治疗(ART)的进步,人类免疫缺陷病毒(PLWH)感染者的预期寿命显著提高。然而,老龄化的PLWH面临着日益增长的非传染性疾病(NCDs)、多种药物和药物相互作用(ddi)的负担,这给他们的管理带来了挑战。本研究调查了韩国≥50岁PLWH中非传染性疾病、多种用药和ddi的患病率及其对生活质量(QOL)的影响。材料与方法:对2022年1月至7月在韩国三所大学医院接受抗逆转录病毒治疗至少三个月的243名年龄≥50岁的PLWH患者进行了横断面研究。通过电子病历和个人访谈收集数据,使用韩国版WHOQOL-HIV BREF量表评估人口统计学、合并症、多种药物、抗逆转录病毒治疗依从性和生活质量。使用利物浦大学HIV药物相互作用数据库分析潜在的ddi,并使用2023年美国老年医学会比尔斯标准确定潜在的不适当药物(PIMs)。结果:合并症的患病率为71.6%,年龄较大的参与者(≥75岁)表现出更高的负担,包括骨病、骨关节炎和痴呆(pv . 76.6, P=0.010)。在81名参与者(33.3%)中发现琥珀色旗ddi,最常见的是二甲双胍和二价阳离子。没有发现危险信号ddi。年龄≥65岁的受试者中有6.6%出现pim。结论:韩国老年PLWH面临着合并症、多药、ddi等方面的重大挑战,对生活质量产生了负面影响。迫切需要综合的、特定年龄的和多学科的护理策略来改善结果并确保老年PLWH的福祉。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Infection and Chemotherapy
Infection and Chemotherapy INFECTIOUS DISEASES-
CiteScore
6.60
自引率
11.90%
发文量
71
审稿时长
22 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信